/

FLNA

Filana Therapeutics, Inc.Pre-market

0.7434−0.03 −3.39%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

0.7600

Prev close

0.7695

Day range

0.73620.7694

52-week range

0.67004.98

Volume

323.25K0.16×

Mkt cap

35.91M

P/E ttm

—

Fwd P/E

—

EPS ttm

-0.8700

Div yield

0.00%

Earnings

Jul 29, 2026

From 52w high

−85.07%

Price Chart

Yahoo Finance · delayed

FLNAOct 13, 2026O 0.7600H 0.7700L 0.7400C 0.7400−0.0300 (−3.90%)Vol 323.50K

SMA 500.8678
SMA 2001.4506

1Y change −81.95% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

FLNA Filana Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −14.94%
1 month: −3.90%
3 months: −32.11%
6 months: −53.46%
Year to date: −62.63%
1 year: −81.95%

Valuation & ownership

Market cap: 35.91M
Enterprise value: −46.77M
P/E (ttm): —
Forward P/E: —
PEG ratio: 1.62
Price / book: 0.56
Price / sales (ttm): —
EV / EBITDA: 3.69
EPS (ttm): -0.8700
EPS (forward): —
Beta (5y monthly): -0.66
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 48.31M
Float: 46.92M
Short % of float: 12.44%
Short ratio (days): 1.16
Held by insiders: 2.05%
Held by institutions: 26.81%
Avg volume (3m): 2.05M
50-day average: 0.8736
200-day average: 1.46
52-week change: −81.95%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 41.5
vs 50-day SMA: −14.73%
vs 200-day SMA: −48.98%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 11.25%
Realised vol (20d, ann.): 164.4%
From 52-week high: −85.14%
From 52-week low: +10.45%

ANR

Analyst Consensus

2 analysts

Consensus

—

Mean target

6.50

+774.36% implied

Low 5.00Median 6.50High 8.00

Recommendation trend

Now2 / 0 / 0
1m ago2 / 0 / 0

Buy / hold / sell counts

DES

About Filana Therapeutics, Inc.

Yahoo Finance profile

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

Sector: Healthcare
Industry: Biotechnology
Employees: 17
Headquarters: Austin, TX, United States
Website: filanatx.com
Officers: Mr. Richard Jon Barry CEO, President & Director
Mr. Eric J. Schoen Chief Financial Officer
Mr. R. Christopher Cook J.D. Chief Operating & Legal Officer
Dr. George Thornton Ph.D. Senior Vice President of Technology

SEAS

Seasonality · FLNA

2007–2026 · monthly returns

Strongest month Sep +18.83%Weakest month Oct −4.67%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	0.5	14.6	-25.9	-14.2	6.2	-22.7	-15.1	-10.9	-1.1	-16.5			−62.5%
2025	0.8	0.8	-37.5	4.0	28.8	-10.0	16.0	8.6	27.6	12.0	-0.3	-39.1	−16.1%
2024	6.4	-4.1	-11.7	9.2	-0.5	-43.9	79.9	29.2	2.5	-12.3	-85.1	-38.5	−89.5%
2023	-5.2	-11.8	-2.3	-3.7	-2.2	8.0	-10.4	-4.6	-20.6	21.1	3.4	8.1	−23.8%
2022	1.3	-3.9	-12.6	-43.8	46.6	-8.1	-41.9	57.6	62.5	-12.9	-4.4	-15.2	−32.4%
2021	190.6	145.1	-7.5	4.1	15.2	58.5	-18.6	-18.2	9.2	-30.5	24.0	-18.3	+540.8%
2020	56.7	-31.2	-26.7	85.9	-72.0	43.9	2.9	-0.9	266.6	-28.7	-6.0	-11.7	+31.2%
2019	37.6	0.9	9.3	-14.7	0.0	10.0	11.6	-17.0	7.1	9.2	13.0	251.4	+511.8%
2018	75.3	-7.3	9.1	13.5	23.7	-79.3	8.7	-54.5	-1.0	16.8	-2.5	-26.1	−78.7%
2017	-1.8	1.8	56.1	-4.5	-36.8	10.4	-17.8	-5.9	26.8	-13.3	13.9	-0.5	+0.3%
2016	-7.4	13.6	21.2	8.5	-3.7	-6.0	23.3	-11.5	-58.2	-44.0	14.3	-10.9	−67.4%
2015	-3.0	-3.6	-0.5	7.9	-3.4	-12.2	9.2	-2.6	-0.5	1.1	8.1	-12.5	−13.8%
2014	-14.4	35.8	-2.7	3.5	-13.0	16.2	-26.8	0.2	-7.3	-55.5	4.0	12.2	−58.2%
2013	1.1	6.9	17.1	20.1	-35.2	-17.2	9.5	8.7	3.4	34.6	25.1	6.1	+79.3%
2012	16.1	-16.8	-1.4	11.9	-7.4	25.1	-21.5	8.2	26.9	-7.5	-31.9	-14.8	−28.7%
2011	-8.3	10.5	39.8	-0.5	4.6	-61.1	24.5	-1.5	0.2	-6.5	-13.0	-1.8	−43.7%
2010	-1.3	14.4	3.6	-4.3	-2.7	-4.8	5.2	-3.2	9.2	24.3	3.8	-15.3	+25.9%
2009	12.2	-31.8	-7.3	12.9	-5.9	20.4	-18.1	15.9	-0.8	0.2	1.4	4.3	−9.5%
2008	-18.3	-2.7	0.2	-17.9	17.1	-2.8	7.8	9.7	4.5	-6.4	-3.9	-32.6	−44.2%
2007	1.2	-12.4	-0.6	-0.9	8.4	3.4	-3.8	11.9	-0.3	9.7	2.2	1.0	+19.1%

INSD

Insider Activity · FLNA

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 29, 2026	Barry Richard JChief Executive Officer	Purchase at price 0.90 - 0.92 per share.	306.8K	$278.13K
Sep 27, 2026	Barry Richard JChief Executive Officer	Purchase at price 0.84 per share.	93.1K	$78.20K
Nov 23, 2025	Anderson Robert Eugene JrDirector	Purchase at price 2.90 per share.	8.6K	$24.94K
Nov 19, 2025	Barry Richard JChief Executive Officer	Purchase at price 2.76 per share.	150K	$414.00K
Nov 18, 2025	Barry Richard JChief Executive Officer	Purchase at price 2.75 per share.	73.4K	$201.81K
Sep 29, 2025	Cook Robert ChristopherChief Operating Officer	Purchase at price 2.91 per share.	13.7K	$39.94K
Sep 21, 2025	Barry Richard JChief Executive Officer	Purchase at price 2.28 per share.	7.2K	$16.35K
Sep 18, 2025	Barry Richard JChief Executive Officer	Purchase at price 2.13 - 2.29 per share.	237.9K	$534.74K
Nov 28, 2024	Schoen Eric J.Chief Financial Officer	Sale at price 3.82 - 3.86 per share.	61.8K	$238.47K
Nov 28, 2024	Schoen Eric J.Chief Financial Officer	Conversion of Exercise of derivative security at price 1.18 per share.	50K	$59.00K
Nov 28, 2024	Kupiec James WilliamOfficer	Sale at price 3.87 per share.	4K	$15.48K

13F

Investors Holding FLNA

latest 13F filings of 29 followed managers

Investors holding FLNA
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$463.6K	0.00%	389.60K	+19%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

FLNA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

FLNA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Filana Therapeutics, Inc.

Seasonality · FLNA

Insider Activity · FLNA

Congress Trades · FLNA

Investors Holding FLNA

Investors Holding FLNA

Congress Trades · FLNA

Insider Activity · FLNA

Seasonality · FLNA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Filana Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News